Crescent Biopharma, Inc. (CBIO)
| Market Cap | 672.22M |
| Revenue (ttm) | 11.88M |
| Net Income | -162.08M |
| EPS | -8.05 |
| Shares Out | 33.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 249,462 |
| Open | 18.70 |
| Previous Close | 18.91 |
| Day's Range | 18.55 - 20.59 |
| 52-Week Range | 8.72 - 27.41 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 29.43 (+45.48%) |
| Earnings Date | Apr 29, 2026 |
About CBIO
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is head... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for CBIO stock is "Strong Buy." The 12-month stock price target is $29.43, which is an increase of 45.48% from the latest price.
News
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multip...
Crescent Biopharma Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The company is advancing a matrix portfolio of next-gen IO agents and ADCs, leveraging a key partnership to accelerate development and data generation. Major clinical data from global trials and collaborations are expected in 2027, with a strong financial position supporting execution.
Crescent Biopharma Transcript: Bank of America Global Healthcare Conference 2026
The team is advancing a dual strategy in oncology with a next-gen bispecific and ADC portfolio, targeting robust data readouts by 2027. Global trials and a key partnership with Kelun-Biotech are accelerating development and supporting broad indication coverage.
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next w...
Crescent Biopharma to Present at May Investor Conferences
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next w...
Crescent Biopharma reports Q1 EPS (70c), consensus (79c)
Reports Q1 revenue $1.04M, consensus $357,140. “Crescent’s execution on the advancement of our pipeline this quarter positions us for meaningful clinical data readouts in 2027 from CR-001, our potenti...
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination...
Crescent Biopharma Quarterly report: Q1 2026
Crescent Biopharma has published its Q1 2026 quarterly earnings report on April 29, 2026.
Crescent Biopharma Earnings release: Q1 2026
Crescent Biopharma released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Crescent Biopharma Proxy statement: Proxy filing
Crescent Biopharma filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Crescent Biopharma Proxy statement: Proxy filing
Crescent Biopharma filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Crescent Biopharma Proxy statement: Proxy filing
Crescent Biopharma filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Crescent Biopharma management to meet with Cantor Fitzgerald
Meeting to be held in San Francisco on April 14, in Denver on April 15 and in New York on April 16 hosted by Cantor Fitzgerald.
Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified oncology portfolio, highlighted by a PD-1/VEGF bispecific and multiple ADCs, with a strategic partnership enabling parallel data generation in China and globally. Key clinical readouts are expected in 2027, supported by strong funding and a focus on best-in-class differentiation.
Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a robust oncology pipeline, highlighted by CR-001 and strategic ADC assets, with multiple studies launching and key data readouts expected in 2027. Strong partnerships and financial position support a data-driven, combination-focused development strategy.
Crescent Biopharma price target lowered to $22 from $25 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Crescent Biopharma (CBIO) to $22 from $25 and keeps a Buy rating on the shares.
Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year
Reports Q4 revenue $10.8M vs .$0 last year. “2025 was a transformational year for Crescent and our efforts to deliver next generation therapies that can improve outcomes for people living…
Crescent Biopharma sees cash runway into 2028
Cash and cash equivalents were $213.2 million as of December 31, 2025, which is anticipated to fund operations into 2028.
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs
Crescent Biopharma Annual report: Q4 2025
Crescent Biopharma has published its Q4 2025 annual report on February 26, 2026.
Crescent Biopharma Earnings release: Q4 2025
Crescent Biopharma released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Crescent Biopharma to Present at March Investor Conferences
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma announces grants of inducement awards
Crescent Biopharma (CBIO) announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 24,600 shares of the Company’s ordin...
Crescent Biopharma announces first patient dosed in ASCENT Phase 1/2 trial
Crescent Biopharma (CBIO) announced that the first patient has been dosed in its global ASCEND Phase 1/2 clinical trial evaluating CR-001, an investigational PD-1 x VEGF bispecific antibody, for the…
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patient...